145 related articles for article (PubMed ID: 36812661)
1. Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
Miret M; Anderson A; Hindocha P; Cirneanu L; Lymperopoulou C; Markov E; Kizito W; Vegni FE
Leuk Res; 2023 Apr; 127():107042. PubMed ID: 36812661
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
[TBL] [Abstract][Full Text] [Related]
4. Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.
Kim JS; Liu Y; Ha KH; Qiu H; Rothwell LA; Kim HC
Cancer Res Treat; 2020 Oct; 52(4):1262-1272. PubMed ID: 32599988
[TBL] [Abstract][Full Text] [Related]
5. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
Jiang S; Zhen H; Jiang H
Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
[TBL] [Abstract][Full Text] [Related]
6. Second Primary Malignancies in Mantle Cell Lymphoma: A US Population-based Study.
Shah BK; Khanal A
Anticancer Res; 2015 Jun; 35(6):3437-40. PubMed ID: 26026107
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
8. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
9. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
Morton LM; Curtis RE; Linet MS; Bluhm EC; Tucker MA; Caporaso N; Ries LA; Fraumeni JF
J Clin Oncol; 2010 Nov; 28(33):4935-44. PubMed ID: 20940199
[TBL] [Abstract][Full Text] [Related]
10. Second primary malignancies after ocular adnexal lymphoma diagnosis.
Loya A; Ramachandran V; Ayaz T; Weng CY
BMC Ophthalmol; 2021 Apr; 21(1):162. PubMed ID: 33827494
[TBL] [Abstract][Full Text] [Related]
11. [Secondary non-Hodgkin's lymphomas].
Cappelaere P
Bull Cancer; 1998 Mar; 85(3):217-31. PubMed ID: 9752310
[TBL] [Abstract][Full Text] [Related]
12. Evidence of an association between non-Hodgkin's lymphoma and skin cancer.
Adami J; Frisch M; Yuen J; Glimelius B; Melbye M
BMJ; 1995 Jun; 310(6993):1491-5. PubMed ID: 7787593
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in Minnesota.
Brewer JD; Shanafelt TD; Khezri F; Sosa Seda IM; Zubair AS; Baum CL; Arpey CJ; Cerhan JR; Call TG; Roenigk RK; Smith CY; Weaver AL; Otley CC
J Am Acad Dermatol; 2015 Feb; 72(2):302-9. PubMed ID: 25479909
[TBL] [Abstract][Full Text] [Related]
14. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
16. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular mortality among patients with non-Hodgkin lymphoma: Differences according to lymphoma subtype.
Abuamsha H; Kadri AN; Hernandez AV
Hematol Oncol; 2019 Aug; 37(3):261-269. PubMed ID: 30916804
[TBL] [Abstract][Full Text] [Related]
19. Risk and survival of second primary malignancies following diagnosis of gastric mucosa-associated lymphoid tissue lymphomas: A population-based study.
Yang Y; Yang Y; Yan S
Curr Probl Cancer; 2021 Dec; 45(6):100735. PubMed ID: 33867153
[TBL] [Abstract][Full Text] [Related]
20. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas--lessons learned from composite and sequential malignancies.
Jaffe ES; Zarate-Osorno A; Medeiros LJ
Semin Diagn Pathol; 1992 Nov; 9(4):297-303. PubMed ID: 1480852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
